2018
DOI: 10.1684/ejd.2018.3411
|View full text |Cite
|
Sign up to set email alerts
|

Pegylated interferon-α2b for local control of Langerhans cell sarcoma

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 10 publications
0
1
0
Order By: Relevance
“…The results of this study highlight potential research into the use of immune checkpoint inhibitors such as pembrolizumab. Another unique case described the results of pegylated interferon-alpha2b for control of cutaneous LCS [60]. The positive results of this study provide a unique insight into the fact that despite aggressive atypica and proliferation the affected cells may still retain properties of dendritic cells.…”
Section: Discussionmentioning
confidence: 64%
“…The results of this study highlight potential research into the use of immune checkpoint inhibitors such as pembrolizumab. Another unique case described the results of pegylated interferon-alpha2b for control of cutaneous LCS [60]. The positive results of this study provide a unique insight into the fact that despite aggressive atypica and proliferation the affected cells may still retain properties of dendritic cells.…”
Section: Discussionmentioning
confidence: 64%